How were Tetraphase Pharmaceuticals' earnings last quarter?
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) announced its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, topping analysts' consensus estimates of ($1.63) by $0.32.
When did Tetraphase Pharmaceuticals' stock split? How did Tetraphase Pharmaceuticals' stock split work?
Tetraphase Pharmaceuticals shares reverse split on the morning of Friday, September 27th 2019. The 1-20 reverse split was announced on Thursday, September 26th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 26th 2019.
Who are some of Tetraphase Pharmaceuticals' key competitors?
Some companies that are related to Tetraphase Pharmaceuticals include Tiziana Life Sciences (TLSA), Longboard Pharmaceuticals (LBPH), Gemini Therapeutics (GMTX), GlycoMimetics (GLYC), Hookipa Pharma (HOOK), Angion Biomedica (ANGN), Galera Therapeutics (GRTX), Millendo Therapeutics (MLND), NexImmune (NEXI), Ainos (AIMD), PhaseBio Pharmaceuticals (PHAS), Ocuphire Pharma (OCUP), Oncorus (ONCR), Neptune Wellness Solutions (NEPT) and ProQR Therapeutics (PRQR). View all of TTPH's competitors..
What other stocks do shareholders of Tetraphase Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Tetraphase Pharmaceuticals investors own include Aurinia Pharmaceuticals (AUPH), Alcoa (AA), General Electric (GE), OPKO Health (OPK), Novavax (NVAX), Bank of America (BAC), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO) and Synergy Pharmaceuticals (SGYP)..
What is Tetraphase Pharmaceuticals' stock symbol?
Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."
What is Tetraphase Pharmaceuticals' stock price today?
One share of TTPH stock can currently be purchased for approximately $2.20.
How much money does Tetraphase Pharmaceuticals make?
Tetraphase Pharmaceuticals has a market capitalization of $15.98 million and generates $7.38 million in revenue each year. The biopharmaceutical company earns $-70.08 million in net income (profit) each year or ($22.85) on an earnings per share basis.
Signals & Forecast
There are mixed signals in the stock today. The Tetraphase Pharmaceuticals stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Support, Risk & Stop-loss
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Is Tetraphase Pharmaceuticals stock A Buy?
Tetraphase Pharmaceuticals holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Insiders are positive buying more shares than they are selling in Tetraphase Pharmaceuticals
In the last 100 trades there were 7.35 million shares bought and 1.57 million shares sold. The last trade was done 565 days ago by Armistice Capital, Llc who sold 1.42 million shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Price Target and Consensus Rating
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Price Target Consensus
Sign-up to receive the latest news and ratings for TTPH and its competitors with MarketBeat's FREE daily newsletter.
Analyst Ratings By Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Average Share Price and Price Target by Month
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Analyst Ratings Frequently Asked Questions
MarketBeat users like Tetraphase Pharmaceuticals stock less than the stock of other Medical companies. 67.13% of MarketBeat users gave Tetraphase Pharmaceuticals an outperform vote while medical companies recieve an average of 67.58% outperform votes by MarketBeat users.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
TTPH Stock Summary
With a year-over-year growth in debt of -92.22%, Tetraphase Pharmaceuticals Inc's debt growth rate surpasses merely 1.81% of about US stocks.
Latest TTPH News From Around the Web
Below are the latest news stories about Tetraphase Pharmaceuticals Inc that investors may wish to consider to help them evaluate TTPH as an investment opportunity.
How many awards did Tri Pointe win in 2021?
AUSTIN, July 16, 2021 (GLOBE NEWSWIRE) -- Tri Pointe Homes, Inc. (NYSE: TPH), one of the largest homebuilders in the US, has won five awards at the 2021 MAX (Marketing and Advertising Excel. Zacks • 12 days ago.
How much is Tri Pointe home in 2021?
Tri Pointe Homes won five 2021 MAX Awards including Best Interior Merchandising of a Detached Home priced from $350,000 to $499,000. The Allendale home design within Tri Pointe Homes’ Capital Collection at Bryson is one of the most versatile plans offered at the new master-planned community in Leander, Texas.
When will Tri Pointe release its results?
(NYSE: TPH) announced today that it will release its financial results for the second quarter of 2021 before the market opens on Thursday, July 22, 2021. The Company will host a conference call on the same day to discuss the results at 7:00 AM Pacific (10:00 AM Eastern). The call will be hosted by Doug Bauer, Chief Executive Officer, Tom Mitchell, Chief Operating Officer, and Glenn Keeler, Chief Financial Officer. Th
Is Tri Pointe a good stock to buy?
Tri Pointe (TPH) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Theravance's (TBPH) Q4 Earnings and Sales Miss Estimates
Theravance (TBPH) reports wider-than-expected loss for the fourth quarter of 2021. Revenues decline year over year.
Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of -43.33% and 4.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the fourth quarter and full year ended December 31, 2021.
